Neoantigens and the tumor microenvironment play important roles in the prognosis of high-grade serous ovarian cancer.

ABSTRACT:

Background

Despite the consistency of patient age, disease stage and treatment options, the prognosis of different high-grade serous ovarian carcinoma (HGSOC) patients is different. Here, we sought to measure predictive biomarkers for distinct responses to platinum-based chemotherapy and immunotherapy benefits.

Methods

Sixteen HGSOC patients receiving debulking surgery and adjuvant first-line combination chemotherapy at Peking Union Medical College Hospital (PUMCH) were enrolled. Whole exome sequencing (WES) and RNA-seq were performed on tumor and normal tissues of these patients.

Results

The tumor mutational burden (TMB) and intratumoral heterogeneity (ITH) of the platinum-resistant group were significantly higher than those of the platinum-sensitive group (P=0.0321

SUBMITTER: Yang H 

PROVIDER: S-EPMC8801100 | biostudies-literature | 2022 Jan

REPOSITORIES: biostudies-literature